Stockscreener 앱 받기
1.25
3.10%
-0.04
시간 외 거래:
1.31
0.06
+4.80%
전일 마감가:
$1.29
열려 있는:
$1.26
하루 거래량:
114.22K
Relative Volume:
0.19
시가총액:
$1.93M
수익:
-
순이익/손실:
$-17.06M
주가수익비율:
-0.0177
EPS:
-70.7173
순현금흐름:
$-14.18M
1주 성능:
-11.35%
1개월 성능:
-48.56%
6개월 성능:
-79.67%
1년 성능:
-99.84%
1일 변동 폭
$1.22
$1.3379
1주일 범위
$1.21
$1.5097
52주 변동 폭
$1.21
$800.00
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
명칭
Cns Pharmaceuticals Inc
전화
1-800-946-9185
주소
2100 WEST LOOP SOUTH, HOUSTON
CNSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
1.25 | 1.93M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-12-28 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | 개시 | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc 주식(CNSP)의 최신 뉴스
CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year - Yahoo Finance
CNS Pharma's Strategic Shift: New Cancer Drug Focus as Losses Shrink 21% - Stock Titan
CNS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga
CNS Pharmaceuticals (NASDAQ:CNSP) Receives Hold Rating from Maxim Group - Defense World
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven? - Yahoo Finance
Market Sentiment Around Loss-Making CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - simplywall.st
CNSP stock touches 52-week low at $1.49 amid sharp annual decline By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Nasdaq Gains 50 Points; US New Home Sales Rise In February - Benzinga
CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects - Benzinga
CNSP stock touches 52-week low at $1.49 amid sharp annual decline - Investing.com
CNS Pharmaceuticals shares tumble after clinical trial results By Investing.com - Investing.com South Africa
CNS Pharmaceuticals shares tumble after clinical trial results - Investing.com India
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme - Yahoo Finance
CNS Pharmaceuticals expands stock sale agreement to $43.5 million - Investing.com
CNS Pharmaceuticals expands stock sale agreement to $43.5 million By Investing.com - Investing.com UK
The International Society for CNS Drug Development (ISCDD) Honors Sharon Mates, PhD, and Steven Paul, MD with Prestigious Leadership Award at 23rd Annual Meeting - Yahoo Finance
Central Nervous System (CNS) Therapeutics Market to Reach USD - openPR
Houston’s Life Sciences Scene Continues Boosting Its Reputation - BioSpace
Xenon Pharmaceuticals Reveals Latest Progress on Revolutionary CNS Drug Development - Stock Titan
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum - Business Wire
Cns Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire
Trimtech closes seed fund round to advance CNS therapeutics pipeline - Pharmaceutical Technology
CNSP stock touches 52-week low at $2.2 amid sharp annual decline - Investing.com Australia
CNSP stock touches 52-week low at $2.2 amid sharp annual decline By Investing.com - Investing.com South Africa
CNS Pharmaceuticals jumps on current cash position update - MSN
CNS Pharmaceuticals secures NASDAQ listing and funding into 2026 By Investing.com - Investing.com South Africa
CNS Pharmaceuticals reports cash position of $14M as of February 26 - TipRanks
CNS Pharmaceuticals secures NASDAQ listing and funding into 2026 - Investing.com
Can CNS Pharmaceuticals' $14M War Chest Deliver on Its Promising Brain Cancer Treatment? - StockTitan
CNS Pharmaceuticals (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical Progress - The Globe and Mail
CNS Pharmaceuticals to implement 1-for-50 reverse stock split - MSN
CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum - Barchart
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference - The Globe and Mail
CNS Pharmaceuticals Advances Berubicin and TPI 287 Projects - MSN
CNSPCNS Pharmaceuticals Latest Stock News & Market Updates - StockTitan
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum - ACCESS Newswire
CNS Pharmaceuticals enacts 1-for-50 reverse stock split - Investing.com
CNSP stock touches 52-week low at $0.08 amid sharp annual decline - Investing.com India
CNS Pharmaceuticals to Implement 1-for-50 Reverse Stock Split; Shares Down -February 19, 2025 at 10:28 am EST - Marketscreener.com
Can CNS Pharmaceuticals' 5 Key Growth Drivers Transform Brain Cancer Treatment? CEO Reveals 2025 Roadmap - StockTitan
Can This Drastic 1:50 Reverse Split Save CNS Pharmaceuticals' Nasdaq Listing? - StockTitan
CNS Pharmaceuticals to present at Glioblastoma Drug Development Summit - TipRanks
Revolutionary Brain Barrier-Crossing Cancer Drug Takes Center Stage at GBM Summit - StockTitan
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit - Yahoo Finance
CNSP stock touches 52-week low at $0.09 amid sharp decline - MSN
CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) - ACCESS Newswire
Why Airbnb Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire
Longwood Fund launches anxiety drug developer with $93.5M investment - The Business Journals
Cns Pharmaceuticals Inc (CNSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):